North America Pharmacokinetics And Pharmacodynamics Market is predicted to reach USD 1.3 billion at a CAGR of 7.9% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global North America Pharmacokinetics And Pharmacodynamics Market”.

The pharmacokinetics and pharmacodynamics market is projected to register a CAGR of 7.09% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the North America Pharmacokinetics and Pharmacodynamics market — LGC Limited, Eurofins Scientific, Creative Biolabs, Creative Bioarray, Quanticate, Pacific BioLabs, Inc., Allucent, Charles River Laboratories, Evotec AG, SGS Société Générale de Surveillance SA. and others.

North America Pharmacokinetics Pharmacodynamics Market Highlights

The North America pharmacokinetics and pharmacodynamics market is accounted to register a CAGR of 7.09% during the forecast period and is estimated to reach USD 1.3 billion by 2032.

The growth of the North America pharmacokinetics and pharmacodynamics market is attributed to the increasing prevalence of chronic diseases, advancements in technology and analytical techniques, and strong healthcare infrastructure. For instance, as per the National Cancer Institute, an estimated 1,806,590 new cancer cases were diagnosed in the US in 2020. Similarly, according to the US Department of Health and Human Services, the prevalence of cancer in the US is 439.2 per 100,000 men and women.

Segment Analysis

Based on service type, the North America pharmacokinetics and pharmacodynamics market has been segmented into pharmacokinetic services, and pharmacodynamic services. The pharmacokinetic services segment is further segmented into drug absorption studies, drug distribution studies, drug metabolism studies, drug excretion studies, and others. pharmacodynamic services further segmented into receptor binding studies, biomarker analysis, and others.

Based on drug type, the North America pharmacokinetics and pharmacodynamics market is bifurcated into small molecules and large molecules.

Based on therapeutic area, the North America pharmacokinetics and pharmacodynamics market has been segmented into oncology, cardiovascular, infectious disease, neurology, immunology, and others.

Based on end user, the North America pharmacokinetics and pharmacodynamics market has been segmented into pharmaceutical and biotechnology companies, academic and research institutions, and others.

Regional Analysis

The North America pharmacokinetics and pharmacodynamics market is segmented into the US and Canada. The US held the largest market share of 82.34% based on region and Canada is anticipated to dominate the overall pharmacokinetics and pharmacodynamics market during the forecast period.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of North America Pharmacokinetics Pharmacodynamics Market Research Report

Key Findings of the Study

• The North America pharmacokinetics and pharmacodynamics market is expected to reach USD 1.3 billion by 2032 at a CAGR of 7.09% during the forecast period.


• The US country held the second largest market share of the North America market, due to increasing prevalence of cardiovascular diseases, increasing demand for biosimilar drugs, and increasing geriatric population.


• LGC Limited, Eurofins Scientific, Creative Biolabs, Creative Bioarray, Quanticate, Pacific BioLabs, Inc., Allucent, Charles River Laboratories, Evotec AG, SGS Société Générale de Surveillance SA. and others are the key players in the market.